Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Avadel and Serenity enter into exclusive negotiations for Noctiva

Aug. 18, 2017

Taiho Pharmaceutical begins enrolling patients in phase II study of TAC-302

Aug. 11, 2017

FDA grants orphan drug designation for blisibimod as treatment of IgA nephropathy

Aug. 10, 2017

Clearance for first-in-human study of ORBCEL-M for diabetic kidney disease

Aug. 7, 2017

FDA grants orphan drug designation to OMS-721 for IgA nephropathy

Aug. 7, 2017

Quark Pharmaceuticals reports positive results from QPI-1002 phase II study

July 28, 2017

Encouraging phase IIa results for DMX-200 in patients with proteinuria

July 14, 2017

Results from phase I trial of oral CR-845 in hemodialysis patients with CKD

July 13, 2017

Bardoxolone methyl granted U.S. orphan drug status for Alport syndrome

July 10, 2017

ADV-7103 granted E.U. orphan drug designation for distal renal tubulopathy acidosis

July 7, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...